TSCAN THERAPEUTICS, INC. (TCRX)

(10% Negative) TSCAN THERAPEUTICS, INC. (TCRX) Announces Delay in enrollment Trials for vivo solid tumor program Due to Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment